Member LoginDividend CushionValue Trap
|
Valuentum
Reports
Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for
any changes.
Latest
Valuentum Commentary
Aug 8, 2013
Why Zoetis’ Second Quarter Was Decent
Pfizer spin-off Zoetis serves a niche animal healthcare market. Aug 5, 2013
Which Sectors Are Leading the Market Higher? And Why Is This Important?
Identifying sector and industry leadership is very important for the institutional money manager as doing so often leads to undervalued firms that are just starting to have their value recognized by the market — Valuentum stocks. Let’s dig into which sectors have been strong and which ones have been weak so far in 2013. Aug 1, 2013
Pfizer and Merck Show Revenue Declines; Pipelines Remain Strong
Pfizer and Merck faced key patent expirations in the second quarter. However, both of their respective pipelines are promising. Jun 20, 2013
Generic Pharmaceuticals: Patent Expiration and Low Global Utilization Rates Create Opportunities
Big Pharma is not dead, but neither are the generics. Let’s take a look at opportunities presented from patent expiry in the US and low generic utilization rates across the globe. We don’t think investors are expecting the “mountain” of opportunities in 2015. Jun 4, 2013
ASCO Reveals That Big Pharma Is Alive
Some good news from Bristol-Myers Squibb, Merck, GlaxoSmithKline, and Amgen showed the promise of immunotherapies for cancer treatment. Jan 30, 2013
Pfizer and Eli Lilly Report Strong Performance; Drug Pipelines Continue to Advance
Let's take a look at Pfizer's and Lilly's fourth-quarter reports. Jan 2, 2013
Fiscal Cliff Averted; Aerospace Rallying
EDAC, Astronics, and Precision Castparts -- three of our favorite companies in aerospace -- are surging! Dec 20, 2012
You Are Ahead of the News As a Valuentum Member
Remember how optimistic we were about economic growth when others were so bearish...did you see the GDP number today? Remember when we warned that President Obama and House Speaker Boehner are still far apart from a deal, despite all of the optimism. Did you see today that the White House will veto Boehner's "Plan B" bill? Dec 18, 2012
Inside the New Abbott: A Lot Like the Old Abbott But Without Humira
We take a dive inside the prospects of the “new” Abbott, which is quite a bit like the old Abbott—minus Humira. Latest News and Media The High Yield Dividend Newsletter, Best Ideas
Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on
this website are for information purposes only and should not be considered a solicitation to buy or sell any
security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s
accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or
omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts
no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a
registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees,
and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.
|
|||||||||||||||||||||
Let’s take a look at the third-quarter performance of a few pharmaceutical firms.